This activity is sponsored by the Dermatology Nurses' Association.

Dermatology Nurses' Association

 

This activity is funded through an educational grant from Abbott.

Abbott

 

 

This free CNE activity is based on presentations given at the CNE satellite symposium titled Patient Profiles In Psoriatic Disease: A Case-Based Approach, which was held on February 3, 2007 in Arlington, Virginia.

Persons who attended the symposium are NOT eligible to receive CNE credit for this online activity. Please note that the course is accredited only for nurses. All other participants receive a certificate of completion.

The Dermatology Nurses' Association (DNA) is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (ANCC-COA).

The DNA must ensure balance, independence, objectivity, and scientific rigor in its educational activities. All faculty are required to disclose relationships with commercial grantors or products. Faculty are also required to identify trade names, investigational products, and unlabeled uses that are discussed in their presentations. Disclosure is included on this Web site so participants may formulate their own judgment regarding the presentations.

© 2007 Emeritus Educational Sciences. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems without permission in writing from Emeritus Educational Sciences.

Target Audience

This activity is designed for dermatology nurses active in the treatment of psoriasis and psoriatic arthritis.

Release Date

May 10, 2007

Expiration Date

May 10, 2008

Term of Offering

This activity has a release date of May 10, 2007, and is valid for 1 year. Requests for credit must be received no later than May 10, 2008. No fee is associated with participation in the CNE activity. To receive credit, participants must watch the entire activity and complete the course test. Upon successful completion of the course and test, participants will receive further instruction regarding instantaneous online receipt of credit. For inquiries regarding technical issues or registration, please e-mail CME/CE Support. Please direct CME content-related questions to:

Continuing Nursing Education
Dermatology Nurses' Association
East Holly Avenue, Box 56
Pittman, NJ 08071-0056
800-454-4DNA
856-589-7463 (fax)
dna@ajj.com
www.dnanurse.org.

Estimated Completion Time

1.25 hours

Faculty

Mary Wiatrowski, RN, DNC
Clinical Coordinator
Texas Dermatology Associates' Specialty
Psoriasis Clinic
Dallas, Texas

Nicole Furfaro, MSN, ARNP
Nurse Practitioner
Seattle Rheumatology Associates
Seattle, Washington

Learning Objectives

Upon completion of this activity, participants should be able to

  • describe the pathophysiology of psoriatic disorders,
  • recognize the classic manifestations of psoriatic disorders,
  • discuss treatment advances involving targeted biologic therapies,
  • summarize and apply new information on the subject of psoriatic arthritis (PsA) to improve diagnosis and management, and
  • evaluate efficacy and safety data involving the tumor necrosis factor-alpha (TNF-α) antagonist agents in the treatment of psoriasis and PsA.

Accreditation and Designation Statement

The Dermatology Nurses' Association (DNA) is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (ANCC-COA).

The DNA is also an approved provider of continuing education in nursing by the California Board of Registered Nursing, BRN CEP Provider No. 05708. This activity will provide 1.25 contact hours.

Provision of contact hours refers only to continuing education activities and does not imply endorsement of any commercial product by ANCC-COA or DNA.

Funding Statement

This activity is funded through an educational grant from Abbott.

Activity Purpose

This activity explains PsA and discusses how early recognition of the disease can prompt treatment and improve long-term outcomes.

Statement of Need

Psoriasis has been diagnosed in almost 6 million Americans. Of those, 6-39% also experience PsA. Clinical studies demonstrate that joint damage occurs in many individuals with psoriasis well before the clinical manifestations of joint disease are present. Early recognition of the associated signs and symptoms of PsA could impact disease management.

Faculty Disclosures

The Dermatology Nurses' Association (DNA) is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation (ANCC-COA).

The DNA must ensure balance, independence, objectivity, and scientific rigor in its educational activities. All faculty are required to disclose relationships with commercial grantors or products. Faculty are also required to identify trade names, investigational products, and unlabeled uses that are discussed in their presentations. Disclosure is included on this Web site so participants may formulate their own judgment regarding the presentations.

Mary Wiatrowski, RN, DNC
Sources of Funding for Research: None.
Consulting Agreements: None.
Speakers Bureau/Honorarium Agreements: Amgen Inc, Genentech, Inc, and Abbott.
Financial Interests/Stock Ownership: None.
Discussion of Off-label, Investigational, or Experimental Drug Use: None.

Mary Wiatrowski received her nursing degree from Trocaire College in Buffalo, New York. She serves as clinical coordinator for Texas Dermatology Associates' Specialty Psoriasis Clinic in Dallas, Texas and has treated psoriasis patients with Alan Menter, MD, for more than a decade. The clinic, one of the largest in the world, has a research department, infusion center, and a phototherapy department. Ms Wiatrowski presented at the American Academy of Dermatologists conventions in 2004, 2005, and 2006 regarding nursing aspects of therapy. She has also served as a guest speaker for the National Psoriasis Foundation and at psoriasis therapy meetings.

Nicole Furfaro, MSN, ARNP
Sources of Funding for Research: None.
Consulting Agreements: None.
Speakers Bureau/Honorarium Agreements: Abbott, Genentech Inc, and Biogen Idec.
Financial Interests/Stock Ownership: None.
Discussion of Off-label, Investigational, or Experimental Drug Use: None.

Nicole Furfaro completed her bachelor of science in nursing at Washington State University and her master's degree as a Family Practice Nurse Practitioner at Seattle University. She is actively involved in direct patient care and research and provides community and professional education on rheumatic diseases and treatments. Ms Furfaro has worked with psoriatic arthritis and other rheumatic diseases for over 12 years. She is currently employed at Seattle Rheumatology Associates, working with Philip Mease, MD.

Instructions to Participants

Course participants must view the slide presentations and complete both a test and a course evaluation to receive continuing nursing education credit. No fees are charged to participate in the program or to receive the certificate. Full instructions are available on the user instructions page.

Disclaimer

The opinions expressed herein are those of the faculty and do not necessarily represent the views of the sponsors, commercial supporters, or publisher. Please review complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Medicine is a constantly changing science, and clearly established therapies are not always available for every condition. New research findings necessitate continual changes in drug and treatment therapies. Reasonable efforts have been made to provide up-to-date, accurate information that is within generally accepted medical standards at the time of publication. However, as medical science is ever evolving, and human error is always possible, the provider, commercial supporters, and publisher (or any other involved party) do not guarantee total accuracy or comprehensiveness of the information in this activity, and they are not responsible for omissions or errors or the results of using information provided in this course. Participants should confirm the accuracy of the information in this activity from other sources. In particular, all drug doses, indications, and contraindications should be confirmed in package inserts.

Click here to view minimum system requirements.